vimarsana.com


 E-Mail
A Monash University study has uncovered for the first time a way to prevent and reverse damage caused by broken-heart syndrome, also known as Takotsubo cardiomyopathy.
Using mouse models, the pre-clinical study published in the acclaimed journal
Signal Transduction and Targeted Therapy, has shown the cardioprotective benefit of a drug called Suberanilohydroxamic acid, or SAHA, dramatically improved cardiac health and reversed the broken-heart. The landmark study used SAHA to target genes and is a world first for Takotsubo cardiomyopathy.
SAHA, currently used for cancer treatment, is approved by the US Food and Drug Administration (FDA) and Australian Therapeutic Goods Administration (TGA), works by providing a protective benefit to genes and in particular the acetylation/deacetylation (Ac/Dc) index, an important process that regulates gene expression.

Related Keywords

Australia ,Monash ,South Australia ,Australian ,Sam El Osta ,Australian Therapeutic Goods Administration ,A Monash University ,Drug Administration ,Monash Central Clinical School ,Monash University ,Signal Transduction ,Targeted Therapy ,Professor Sam El Osta ,Takosubo Like Myocardial Injury ,Media Enquiries ,ஆஸ்திரேலியா ,மோனாஷ் ,தெற்கு ஆஸ்திரேலியா ,ஆஸ்திரேலிய ,மோனாஷ் மைய மருத்துவ பள்ளி ,மோனாஷ் பல்கலைக்கழகம் ,சமிக்ஞை கடத்தல் ,இலக்கு சிகிச்சை ,மீடியா விசாரணைகள் ,

© 2025 Vimarsana

vimarsana.com © 2020. All Rights Reserved.